Sort
21,281 grants matching “influenza”
MULTISITE EPIDEMIOLOGICAL AND VIROLOGICAL MONITORING OF INFLUENZA VIRUS SURVEILLA
$1,000,000Devendra Tarachand Mourya · Indian Council Of Medical Research · U51 · FY2011 · IP
VACCINE AND TREATMENT EVALUATION UNITS
$1,000,000David Bernstein · Cincinnati Childrens Hosp Med Ctr · N01 · FY2011 · AI
Surveillance and Response to Avian and Pandemic Influenza by Regional Offices....
$1,000,000Adamou A. Yada · World Health Organization--Afro · U51 · FY2007 · CI
Enhanced Surveillance for New Vaccine Preventable Diseases
$1,000,000Julie Anne Boom · Texas Children'S Hospital · U01 · FY2017 · IP
Microarray Patch for Broadly Protective Seasonal Influenza Vaccination
$1,000,000Kathryn Kosuda · Vaxess Technologies, Inc. · SB1 · FY2021 · AI
Enhanced Surveillance for New Vaccine Preventable Diseases
$1,000,000Janet A Englund · Seattle Children'S Hospital · U01 · FY2019 · IP
Microarray Patch for Broadly Protective Seasonal Influenza Vaccination
$1,000,000Kathryn Kosuda · Vaxess Technologies, Inc. · SB1 · FY2022 · AI
Influenza Preparedness in the Americas Region
$1,000,000Albino Belotto · Pan American Health Organization · U51 · FY2007 · CI
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients
$1,000,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
Novel anti-viral agents to treat influenza
$1,000,000Dipanwita Basu · Alexander Biodiscoveries, Llc · R44 · FY2015 · AI
Respiratory Virus Vaccine and Adjuvant Exploration
$1,000,000Ralph S Baric · Univ Of North Carolina Chapel Hill · U01 · FY2020 · AI
Novel anti-viral agents to treat influenza
$1,000,000Dipanwita Basu · Alexander Biodiscoveries, Llc · R44 · FY2014 · AI
Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)
$1,000,000Mallikarjun Srivatsan · Accurius Therapeutics, Inc. · R44 · FY2024 · CA
STRENGHTENING & INTEGRATING SURVEILLANCE & RESPONSE TO SEASONAL INFLUENZA
$1,000,000Monir Islam · World Health Organization · U51 · FY2011 · IP
DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine
$1,000,000Kenneth C Bagley · Orlance, Inc. · R44 · FY2021 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AVIAN INFLUENZA VIRUSES (AIV) ARE ENDEMIC IN CERTAIN WILD BIRD POPULATIONS, AND FROM THERE, SPILL OVER INTO DOMESTIC BIRDS AND HUMAN POPULATIONS WHERE THEY CAUSE OUTBREAKS OF SEVERE DISEASE. SOME STRAINS OF AIV POSE A GREATER THREAT THAN OTHERS, BECAUSE OF A COMBINATION OF THEIR PATHOGENICITY, GEOGRAPHIC AND HOST RANGE; EXEMPLIFIED IN RECENT YEARS BY FOUR MAJOR INCURSIONS OF H5 AND H7 SUBTYPE VIRUSES. SURVEILLANCE BACKED UP BY LABORATORY ASSESSMENT OF THESE TRAITS UNDERPIN ATTEMPTS TO RISK ASSESS AND PREDICT BEHAVIOUR OF A HIGHLY MUTABLE VIRUS. THIS SURVEILLANCE EFFORT, COUPLED WITH THE DEVELOPMENT OF SEQUENCING TECHNOLOGY HAS LED TO AN EXPONENTIAL RISE INTHE AMOUNT OF VIRAL SEQUENCE DATA, BOTH AT CONSENSUS LEVEL AND (VIA NEXT GENERATION SEQUENCING [NGS]) AT QUASI-SPECIES LEVEL. IN PARALLEL, RECENT ADVANCES IN PHYLODYNAMIC MODELLING TECHNIQUES (INCLUDING STRUCTURED COALESCENTS, MULTI-SPECIES BIRTH-DEATH MODELS AND INTEGRATION OF TIME-DEPENDENT PREDICTORS IN GENERALISED LINEAR MODEL PHYLOGEOGRAPHIC APPROACHES HAVE PROVIDED METHODS TO FULLY USE THIS WEALTH OF DATA. ACCORDINGLY, WE HYPOTHESISE THAT, FOR THE FIRST TIME, PROPERLY PARAMETERISED MATHEMATICAL MODELS OF VIRAL EVOLUTION WITH GENUINEPREDICTIVE VALUE CAN NOW BE CONSTRUCTED. WE WILL GENERATE THESE MODELS AND PRODUCE SPREAD AND HOST RANGE RISK MAPS FOR SPECIFIC AIV STRAINS THAT CAN BE USED TO INFORM VACCINATION AND OTHER CONTROL STRATEGIES.
$1,000,000Agricultural Research Service · · FY2021 · National Institute of Food and Agriculture
Rapid, disposable, nucleic acid diagnostic device for multiplexed point of care f
$1,000,000Hong Cai · Mesa Tech International, Inc. · R44 · FY2016 · AI
Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia
$1,000,000Jodi K Craigo · Cytoagents, Inc. · R44 · FY2022 · AI
African Americans in Health Science Research: A University, Community, and Faith-
$1,000,000Kathy J Goggin · University Of Missouri Kansas City · RC4 · FY2010 · MD
Identification of Novel Broad Spectrum Influenza Virus Inhibitors
$1,000,000Arnab Basu · Microbiotix, Inc · R44 · FY2013 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AIRBORNE ANIMAL DISEASES ARE DIFFICULT TO CONTAIN IN TODAY'S AGRICULTURAL SETTINGS. TO IMPROVE BIOCONTAINMENT STRATEGIES AND MITIGATE AEROSOL TRANSMISSION OF IMPORTANT SWINE PATHOGENS, WE PROPOSE A MULTITIERED APPROACH TO INVESTIGATE AND OPTIMIZE A NOVEL ELECTROSTATIC PRECIPITATOR (ESP) DESIGN TOWARDS BIOCONTAINING AEROSOL TRANSMITTED SWINE DISEASES. WE HYPOTHESIZE THAT A CUSTOM DESIGNED ESP TECHNOLOGY, BOTH WITH STANDARD WIRE DISCHARGE ELECTRODES TO IONIZE PARTICLES AND DRIVE COLLECTION, AS WELL AS SECONDARY ELECTRODES OPERATED TO PRODUCE REACTIVE OXYGEN SPECIES, WILL ENABLE NEW BIOCONTAINMENT MEASURES TO PROTECT SWINE BARNS FROM AIRBORNE VIRUS TRANSPORT BY THEIR UTILIZATION ON THE AIR INTAKE, AND THEN TRANSMISSION FROM BARNS BY THEIR UTILIZATION ON THE EXHAUST AIR. WE WILL PERFORM ENGINEERING EVALUATIONS OF THE PHYSICAL PERFORMANCE, AND DIRECTLY EXAMINE ESP EFFECTS ON AIRBORNE PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) VIRUS AND INFLUENZA A VIRUS (IAV), WHICH ARE TWO OF THE MOST IMPORTANT VIRUSES AFFECTING PIGS IN THE U.S. ANIMAL STUDIES WILL BE USED TO ASSESS THE IMPACT OF THE ESP TECHNOLOGY ON VIRUS AIRBORNE TRANSMISSION BETWEEN INFECTED AND SENTINEL ANIMALS. WE WILL INTEGRATE THESE AIMS WITH EDUCATIONAL AND EXTENSION EFFORTS, INCLUDING THE DEVELOPMENT OF COURSES IN AIRBORNE DISEASE TRANSMISSION, BIOSECURITY AND TECHNOLOGIES, AND PRESENTATION OF WORKSHOPS TO ADVANCE AWARENESS, TECHNICAL UNDERSTANDING, AND USE OF TECHNOLOGIES TO PREVENT THE INTRODUCTION AND DISSEMINATION OF AIRBORNE DISEASES IN ANIMAL POPULATIONS AMONGST PRODUCERS, POLICYMAKERS, AND OTHER STAKEHOLDERS. OUR PROPOSAL WILL ENABLE RAPID RESPONSE TO DISEASES THAT POSE LARGE-SCALE BIOSECURITY THREATS IN ANIMAL PRODUCTION, INCLUDING EXISTING AND IMMINENT THREATS BY MITIGATING DISEASE SPREAD REGIONALLY.
$1,000,000Regents Of The University Of Minnesota · · FY2021 · National Institute of Food and Agriculture
Respiratory Virus Vaccine and Adjuvant Exploration
$1,000,000Ralph S Baric · Univ Of North Carolina Chapel Hill · U01 · FY2019 · AI
DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine
$1,000,000Kenneth C Bagley · Orlance, Inc. · R44 · FY2019 · AI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
$1,000,000Jeffrey S Glenn · Stanford University · R01 · FY2017 · AI
Vaccine and Treatment Evaluation Units
$1,000,000David Bernstein · Cincinnati Childrens Hosp Med Ctr · N01 · FY2011 · AI